Analysts See $-0.99 EPS for Protagonist Therapeutics, Inc. (PTGX)

February 12, 2018 - By Vivian Park

 Analysts See $ 0.99 EPS for Protagonist Therapeutics, Inc. (PTGX)

Analysts expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to report $-0.99 EPS on March, 6.They anticipate $0.32 EPS change or 47.76 % from last quarter’s $-0.67 EPS. After having $-0.29 EPS previously, Protagonist Therapeutics, Inc.’s analysts see 241.38 % EPS growth. The stock increased 3.23% or $0.55 during the last trading session, reaching $17.58. About 107,439 shares traded. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has 0.00% since February 12, 2017 and is . It has underperformed by 16.70% the S&P500.

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide chemical entities to address various unmet medical needs. The company has market cap of $360.03 million. It primarily focuses on developing oral peptide drugs. It currently has negative earnings. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin-specific antagonist that is in phase II clinical trial for the treatment of inflammatory bowel disease ; and PTG-200, an interleukin-23 receptor specific antagonist, which is under pre-clinical development stage for the treatment of IBD.

More notable recent Protagonist Therapeutics, Inc. (NASDAQ:PTGX) news were published by: which released: “Protagonist Therapeutics Announces Proposed Public Offering of Common Stock” on October 11, 2017, also with their article: “Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 …” published on November 09, 2017, published: “Protagonist Therapeutics Inc.” on October 18, 2017. More interesting news about Protagonist Therapeutics, Inc. (NASDAQ:PTGX) were released by: and their article: “Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual …” published on January 31, 2018 as well as‘s news article titled: “Protagonist Therapeutics Granted Two New US Patents for Peptide Drug …” with publication date: January 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: